Conclusion: Octreotide LAR significantly lengthens time to tumor progression compared with placebo in patients with functionally active and inactive metastatic midgut NETs.
- Dr. Michael J. Demeure’s Power Point Presentation (8.5MB PDF) from the AAES meeting in Madison, WI, May 2009
Comprehensive description of neuroendocrine tumors: symptoms, diagnosis and treatment. Presented here with permission from Dr. Demeure.
Michael J. Demeure, MD, MBA
Endocrine & Cancer Surgery